V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Arcellx Executive Compensation (FY24)

ACLX · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Rami Elghandour
Latest say-on-pay support
=
May 28, 2025
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Arcellx brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): May 28, 2025
4 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Arcellx brief$1,500Get the executive brief
Velarion Member, one year
169 figures on this page: 167 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Rami Elghandour: $24,964,306 → $21,402,668 (14.3% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Arcellx's chief executive and what were they paid?
Rami Elghandour, Chief Executive Officer, received $21,402,668 in total compensation for fiscal 2024. Compared with the $24,964,306 reported for fiscal 2023, Elghandour's total was 14.3% lower.
What was Arcellx's say-on-pay result?
For fiscal 2024, the say-on-pay proposal drew 80.8% support at the meeting held May 28, 2025.
Which companies are in Arcellx's peer group?
Companies named in the disclosed peer group include Akero Therapeutics, Inc., Allogene Therapeutics, Inc., Arcus Biosciences, Inc., Arrowhead Pharmaceuticals, Inc. and Arvinas, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rami Elghandour
Chief Executive Officer
◇◇◇◇——◇◇
Christopher Heery
Chief Medical Officer
◇◇◇◇——◇◇
Michelle Gilson
Chief Financial Officer
◇◇◇◇——◇— not reconciled
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rami Elghandour
Chief Executive Officer
◇◇◇◇——◇◇
Christopher Heery
Chief Medical Officer
◇◇◇◇——◇◇
Michelle Gilson
Chief Financial Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rami Elghandour
Chief Executive Officer
◇◇◇◇——◇◇
Michelle Gilson
Chief Financial Officer
◇◇◇◇——◇◇
Christopher Heery
Chief Medical Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher HeeryOPTION◇——◇—◇◇
Christopher HeeryRSU◇——◇——◇
Michelle GilsonOPTION◇——◇—◇◇
Michelle GilsonRSU◇——◇——◇
Rami ElghandourOPTION◇——◇—◇◇
Rami ElghandourRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Rami ElghandourPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇1/2/2034
Option◇—◇6/9/2031
Option◇—◇6/9/2031
Option◇—◇2/3/2032
Option◇—◇9/28/2032
Option◇—◇1/3/2033
Michelle GilsonPSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇5/23/2032
Option◇—◇9/28/2032
Option◇—◇1/3/2033
Option◇—◇1/2/2034
Christopher HeeryPSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇1/3/2033
Option◇—◇6/9/2031
Option◇—◇6/9/2031
Option◇—◇2/3/2032
Option◇—◇9/28/2032
Option◇—◇1/2/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Rami Elghandour
Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Lubner
◇—◇———◇
Ali Behbahani
◇—◇———◇
Jill Carroll
◇—◇———◇
Derek Yoon
◇—◇———◇
Kavita Patel
◇—◇———◇
Olivia Ware
◇—◇———◇
Kristin Myers, Rami Elghandour and Andrew Galligan served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Akero Therapeutics, Inc. AKRO
  • Allogene Therapeutics, Inc. ALLO
  • Arcus Biosciences, Inc. RCUS
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Arvinas, Inc. ARVN
  • Beam Therapeutics, Inc. BEAM
  • Cerevel Therapeutics Holdings, Inc. CERE
  • CRISPR Therapeutics, AG CRSP
  • Denali Therapeutics, Inc. DNLI
  • Intellia Therapeutics, Inc. NTLA
  • Lyell Immunopharma, Inc. LYEL
  • Morphic Holding, Inc. MORF
  • Pliant Therapeutics, Inc. PLRX
  • Relay Therapeutics, Inc. RLAY
  • Replimune Group, Inc. REPL
  • Revolution Medicines, Inc. RVMD
  • Vaxcyte, Inc. PCVX
  • Zentalis Pharmaceuticals, Inc. ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024May 28, 2025=◇◇◇
2023May 24, 2024=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Rami Elghandour (Chief Executive Officer), FY2024 total compensation $21,402,668 (base salary $653,288) [exec_comp, SEC accession 0001193125-25-084363, filed 2025-04-17]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Arcellx files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Arcellx disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Arcellx sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Arcellx's disclosed peer group is defensible, who names Arcellx back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
169 figures on this page: 167 cited to the filing that reported them, 2 calculated from figures it prints.
167 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001193125-25-129522
  2. 0001193125-25-084363
    Compensation Discussion and Analysis · Director Compensation · EXECUTIVE COMPENSATION · Grants of Plan-Based Awards in 2024 · and 2 more sections
  3. 0001193125-24-148245
  4. 0001193125-24-093275
    Summary Compensation Table for Fiscal 2023
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Arcellx executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/ACLX (accessed 2026).
Short form: data: Velarion

The Arcellx brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Arcellx and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Arcellx discloses

The companies named in ACLX's own disclosed peer group.

Akero Therapeutics, Inc.Allogene Therapeutics, Inc.Arcus Biosciences, Inc.Arrowhead Pharmaceuticals, Inc.Arvinas, Inc.Beam Therapeutics, Inc.Cerevel Therapeutics Holdings, Inc.CRISPR Therapeutics, AGDenali Therapeutics, Inc.Intellia Therapeutics, Inc.Lyell Immunopharma, Inc.Morphic Holding, Inc.Pliant Therapeutics, Inc.Relay Therapeutics, Inc.Replimune Group, Inc.Revolution Medicines, Inc.Vaxcyte, Inc.Zentalis Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy